Abstract
GLP1R-based obesity therapies can reduce lean muscle and energy expenditure via adaptive thermogenesis (also known as metabolic adaptation), leading to weight plateaus and regain. Defining the role of muscle energy expenditure in mediating these effects is critical to improving next-generation treatments and sustaining long-term weight loss.